You are here: Industry Insights > Breast Cancer

News List

US nod for Roche's breast cancer combo pharmatimes
June 30, 2020
US regulators have approved Roche's Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, for the treatment of early and metastatic HER2-positive breast cancer.
Roche's Tecentriq shows promise in early triple-negative breast cancer pharmatimes
June 22, 2020
Roche's Tecentriq (atezolizumab) in combination with chemotherapy has improved treatment response in people with early triple-negative breast cancer (TNBC), raising hopes for a new therapeutic option for the condition.
Final NHS green light for Roche's Kadcyla pharmatimes
June 11, 2020
NICE has published final guidance backing NHS use of Roche's Kadcyla (trastuzumab emtansine) for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive early breast cancer.
Pfizer's Ibrance 'unlikely' to hit key early breast cancer goal pharmatimes
June 02, 2020
Pfizer's bid to develop Ibrance (palbociclib) for a certain form of early breast cancer has hit a critical setback after an early analysis of data concluded that it the drug was unlikely to hit its primary goal.
Kisqali Shows Overall Survival Benefit in HR+/HER2- advanced breast cancer americanpharmaceuticalreview
June 02, 2020
Kisqali Shows Overall Survival Benefit in HR+/HER2-Advanced Breast Cancer.
NICE u-turn backs Roche's Tecentriq for triple negative breast cancer pharmatimes
May 27, 2020
NICE is now backing NHS use of Tecentriq (atezolizumab) with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer, following an “improved offer” from drugmaker Roche.
UK’s NICE recommends Roche breast cancer drug Kadcyla pharmaceutical-technology
May 12, 2020
The National Institute for Health and Care Excellence (NICE) in the UK has recommended the use of Roche’s Kadcyla (trastuzumab emtansine) to treat certain patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
FDA approves new therapy for triple negative breast cancer that has spread, not responded to other treatments expresspharma
April 23, 2020
The US Food and Drug Administration granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body.
Seattle Genetics gets FDA nod for breast cancer drug Tukysa pharmaceutical-business-review
April 22, 2020
Seattle Genetics has secured approval from the US Food and Drug Administration (FDA) for its Tukysa (tucatinib) to treat people with advanced unresectable or metastatic HER2-positive breast cancer.
FDA Approves Treatment Option for HER2-Positive Metastatic Breast Cancer americanpharmaceuticalreview
April 21, 2020
As part of Project Orbis, the U.S. Food and Drug Administration (FDA) approved Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page